© 1992 Oxford University Press
research-article |
Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds
Division of Nutritional Carcinogenesis, American Health Foundation Valhalla, NY 10595
1Chemoprevention Branch, Division of Cancer Control and Prevention, National Cancer Institute Bethesda, MD 20856, USA
The inhibitory effect of 40 and 80% maximum tolerated dose (MTD) levels of piroxicam, ibuprofen, ketoprofen and glycyrrhetinic acid on colon carcinogenesis was investigated in male F344 rats. The MTD levels of piroxicam, ibuprofen, ketoprofen and glycyrrhetinic acid as determined in male E344 rats were 500, 500, 250 and 3000 p.p.m. respectively. At 5 weeks of age, groups of male F344 rats were fed the control (AIN-76A) diet and 40 and 80% MTD levels of each test agent in ALN-76A diet. At 7 weeks of age, all animals except the vehicle (saline)-treated controls received azoxymethane (AOM) at a dose rate of 15 mg/kg body wt, once weekly for 2 weeks. All animals were necropsied 50 weeks after the second AOM injection and colon tumor incidences were compared among the groups fed the control diet and chemopreventive agents. Animals fed 400 (80% MTD) and 200 p.p.m. (40% MTD) of piroxicam, 400 p.p.m. (80% MTD) of ibuprofen and 200 p.p.m. (80% MTD) of ketoprofen showed a significant inhibition of colon tumorigenesis as compared to those fed the control diet. Results analyzed by the linear regression method suggested a dose-dependent inhibition of colon carcinogenesls with increasing levels of piroxicam or ibuprofen. In contrast, glycyrrhetinic acid had no measurable chemopreventive effect on colon carcinogenesis.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  W. Tan, J. Wu, X. Zhang, Y. Guo, J. Liu, T. Sun, B. Zhang, D. Zhao, M. Yang, D. Yu, et al. Associations of functional polymorphisms in cyclooxygenase-2 and platelet 12-lipoxygenase with risk of occurrence and advanced disease status of colorectal cancer Carcinogenesis, June 1, 2007; 28(6): 1197 - 1201. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. F. Lamour and C. E. Chalfant Ceramide-1-phosphate: The "missing" link in eicosanoid biosynthesis and inflammation Mol. Interv., December 1, 2005; 5(6): 358 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Yao, W. Zhou, S. Sangha, A. Albert, A. J. Chang, T. C. Liu, and M. M. Wolfe Effects of Nonselective Cyclooxygenase Inhibition with Low-Dose Ibuprofen on Tumor Growth, Angiogenesis, Metastasis, and Survival in a Mouse Model of Colorectal Cancer Clin. Cancer Res., February 15, 2005; 11(4): 1618 - 1628. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Kawamori, T. Kitamura, K. Watanabe, N. Uchiya, T. Maruyama, S. Narumiya, T. Sugimura, and K. Wakabayashi Prostaglandin E receptor subtype EP1 deficiency inhibits colon cancer development Carcinogenesis, February 1, 2005; 26(2): 353 - 357. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. S. Carlton, R. Gopalakrishnan, A. Gupta, B. W. Liston, S. Habib, M. A. Morse, and G. D. Stoner Piroxicam Is an Ineffective Inhibitor of N-Nitrosomethylbenzylamine-induced Tumorigenesis in the Rat Esophagus Cancer Res., August 1, 2002; 62(15): 4376 - 4382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. J. Thun, S. J. Henley, and C. Patrono Nonsteroidal Anti-inflammatory Drugs as Anticancer Agents: Mechanistic, Pharmacologic, and Clinical Issues J Natl Cancer Inst, February 20, 2002; 94(4): 252 - 266. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. L. Wiesner, P. Platzer, S. Buxbaum, S. Lewis, M. MacMillen, J. Olechnowicz, J. Willis, A. Chakravarti, R. C. Elston, and S. D. Markowitz Testing for Colon Neoplasia Susceptibility Variants at the Human COX2 Locus J Natl Cancer Inst, April 18, 2001; 93(8): 635 - 639. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Calaluce, D. L. Earnest, D. Heddens, J. G. Einspahr, D. Roe, C. L. Bogert, J. R. Marshall, and D. S. Alberts Effects of Piroxicam on Prostaglandin E2 Levels in Rectal Mucosa of Adenomatous Polyp Patients: A Randomized Phase IIb Trial Cancer Epidemiol. Biomarkers Prev., December 1, 2000; 9(12): 1287 - 1292. [Abstract] [Full Text]
|
|
|
|
|
|
L. Tessitore, A. Davit, I. Sarotto, and G. Caderni Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21CIP expression Carcinogenesis, August 1, 2000; 21(8): 1619 - 1622. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, H. Kohno, R. Shimada, S. Kagami, F. Yamaguchi, S. Kataoka, T. Ariga, A. Murakami, K. Koshimizu, and H. Ohigashi Prevention of colonic aberrant crypt foci by dietary feeding of garcinol in male F344 rats Carcinogenesis, June 1, 2000; 21(6): 1183 - 1189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H-H. S. Chow, D. L. Earnest, D. Clark, N. Mason-Liddil, C. B. Kramer, J. G. Einspahr, J. M. Guillen-Rodriguez, D. J. Roe, W. Malone, J. A. Crowell, et al. Effect of Subacute Ibuprofen Dosing on Rectal Mucosal Prostaglandin E2 Levels in Healthy Subjects with a History of Resected Polyps Cancer Epidemiol. Biomarkers Prev., April 1, 2000; 9(4): 351 - 356. [Abstract] [Full Text]
|
|
|
|
|
|
R. E. Harris, G. A. Alshafie, H. Abou-Issa, and K. Seibert Chemoprevention of Breast Cancer in Rats by Celecoxib, a Cyclooxygenase 2 Inhibitor Cancer Res., April 1, 2000; 60(8): 2101 - 2103. [Abstract] [Full Text]
|
|
|
|
|
|
B. S. Reddy, Y. Hirose, R. Lubet, V. Steele, G. Kelloff, S. Paulson, K. Seibert, and C. V. Rao Chemoprevention of Colon Cancer by Specific Cyclooxygenase-2 Inhibitor, Celecoxib, Administered during Different Stages of Carcinogenesis Cancer Res., January 1, 2000; 60(2): 293 - 297. [Abstract] [Full Text]
|
|
|
|
|
|
K. Watanabe, T. Kawamori, S. Nakatsugi, T. Ohta, S. Ohuchida, H. Yamamoto, T. Maruyama, K. Kondo, F. Ushikubi, S. Narumiya, et al. Role of the Prostaglandin E Receptor Subtype EP1 in Colon Carcinogenesis Cancer Res., October 1, 1999; 59(20): 5093 - 5096. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Tanaka, K. Kawabata, M. Kakumoto, H. Makita, J. Ushida, S. Honjo, A. Hara, H. Tsuda, and H. Mori Modifying effects of a flavonoid morin on azoxymethane-induced large bowel tumorigenesis in rats Carcinogenesis, August 1, 1999; 20(8): 1477 - 1484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. S. Reddy, T. Kawamori, R. A. Lubet, V. E. Steele, G. J. Kelloff, and C. V. Rao Chemopreventive Efficacy of Sulindac Sulfone against Colon Cancer Depends on Time of Administration during Carcinogenic Process Cancer Res., July 1, 1999; 59(14): 3387 - 3391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Coffey, C. J. Hawkey, L. Damstrup, R. Graves-Deal, V. C. Daniel, P. J. Dempsey, R. Chinery, S. C. Kirkland, R. N. DuBois, T. L. Jetton, et al. Epidermal growth factor receptor activation induces nuclear targeting of cyclooxygenase-2, basolateral release of prostaglandins, and mitogenesis in polarizing colon cancer cells PNAS, January 21, 1997; 94(2): 657 - 662. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Castaño, M. Dalmau, M. Martí, F. Berrocal, R. Bartrons, and J. Gil Inhibition of DNA Synthesis by Aspirin in Swiss 3T3 Fibroblasts J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 366 - 372. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. H. Liu, S.-H. Chang, K. Narko, O. C. Trifan, M.-T. Wu, E. Smith, C. Haudenschild, T. F. Lane, and T. Hla Overexpression of Cyclooxygenase-2 Is Sufficient to Induce Tumorigenesis in Transgenic Mice J. Biol. Chem., May 18, 2001; 276(21): 18563 - 18569. [Abstract] [Full Text] [PDF]
|
|